427 related articles for article (PubMed ID: 25742792)
41. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
[TBL] [Abstract][Full Text] [Related]
42. Isoobtusilactone A induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells.
Kuo PL; Chen CY; Hsu YL
Cancer Res; 2007 Aug; 67(15):7406-20. PubMed ID: 17671211
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
44. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice.
Lin YJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):65-72. PubMed ID: 19343002
[TBL] [Abstract][Full Text] [Related]
45. Rationally designed hecogenin thiosemicarbazone analogs as novel MEK inhibitors for the control of breast malignancies.
Elsayed HE; Ebrahim HY; Haggag EG; Kamal AM; El Sayed KA
Bioorg Med Chem; 2017 Dec; 25(24):6297-6312. PubMed ID: 29066046
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and pro-apoptotic effects of new sulfonamide derivatives via activating p38/ERK phosphorylation in cancer cells.
Cumaoglu A; Dayan S; Agkaya AO; Ozkul Z; Ozpozan NK
J Enzyme Inhib Med Chem; 2015 Jun; 30(3):413-9. PubMed ID: 25198886
[TBL] [Abstract][Full Text] [Related]
47. The synthetic β-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway.
Hung AC; Tsai CH; Hou MF; Chang WL; Wang CH; Lee YC; Ko A; Hu SC; Chang FR; Hsieh PW; Yuan SS
Cancer Lett; 2016 Feb; 371(2):251-61. PubMed ID: 26683774
[TBL] [Abstract][Full Text] [Related]
48. Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity.
Nunes PSG; da Silva G; Nascimento S; Mantoani SP; de Andrade P; Bernardes ES; Kawano DF; Leopoldino AM; Carvalho I
Bioorg Chem; 2021 Aug; 113():104982. PubMed ID: 34020277
[TBL] [Abstract][Full Text] [Related]
49. Structure-based drug design and biological evaluation of 2-acetamidobenzothiazole derivative as EGFR kinase inhibitor.
Gabr MT; El-Gohary NS; El-Bendary ER; El-Kerdawy MM
J Enzyme Inhib Med Chem; 2015 Feb; 30(1):160-5. PubMed ID: 24601650
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
[TBL] [Abstract][Full Text] [Related]
51. Resveratrol mediated cell death in cigarette smoke transformed breast epithelial cells is through induction of p21Waf1/Cip1 and inhibition of long patch base excision repair pathway.
Mohapatra P; Satapathy SR; Das D; Siddharth S; Choudhuri T; Kundu CN
Toxicol Appl Pharmacol; 2014 Mar; 275(3):221-31. PubMed ID: 24467951
[TBL] [Abstract][Full Text] [Related]
52. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
Sheng Y; You Y; Chen Y
Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
[TBL] [Abstract][Full Text] [Related]
53. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
[TBL] [Abstract][Full Text] [Related]
54. [Effect of sodium aescinate in inducing human breast cancer MCF-7 cells apoptosis by inhibiting AKT, ERK and upstream signal SRC activity].
Qi SM; Lv J; Meng Y; Qi ZL; Ling LF
Zhongguo Zhong Yao Za Zhi; 2015 Aug; 40(16):3267-72. PubMed ID: 26790305
[TBL] [Abstract][Full Text] [Related]
55. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
[TBL] [Abstract][Full Text] [Related]
56. Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.
Lim J; Kelley EH; Methot JL; Zhou H; Petrocchi A; Chen H; Hill SE; Hinton MC; Hruza A; Jung JO; Maclean JK; Mansueto M; Naumov GN; Philippar U; Raut S; Spacciapoli P; Sun D; Siliphaivanh P
J Med Chem; 2016 Jul; 59(13):6501-11. PubMed ID: 27329786
[TBL] [Abstract][Full Text] [Related]
57. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230
[TBL] [Abstract][Full Text] [Related]
59. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
[TBL] [Abstract][Full Text] [Related]
60. Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK pathway in human breast cancer MCF-7 cells.
Song X; Wei Z; Shaikh ZA
Toxicol Appl Pharmacol; 2015 Aug; 287(1):26-34. PubMed ID: 26006730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
